TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI-MedSci.cn

TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI

Han, JY; Sequist, LV; Ahn, MJ; Cho, BC; Yu, H; Kim, SW; Yang, JCH; Lee, JS; Su, WC; Kowalski, D; Orlov, S; Cantarini, M; Verheijen, RB; Mellemgaard, A; Frewer, P; Ou, X; Oxnard, G

ANNALS OF ONCOLOGY, 2019; 30 ():

科室
- - 订阅+
  - 更多科室
工具
服务